Rare Disease Day 2011 – "Rare but Equal" - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Rare Disease Day 2011 – "Rare but Equal"


ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Organization for Rare Diseases (EURORDIS), an alliance of patient organizations and individuals, celebrated its fourth Rare Disease Day on Feb. 28, 2011. With a focus this year on equality for patients suffering from rare diseases, the day aims to advocate equal access to healthcare, social services, medicines COMMA and treatments. Awareness-raising activities took place across Europe, but also in the US, Canada, China, and Japan.

Around 30 million people in the European Union suffer from a rare disease. To bring more drugs to market, the EU offers incentives to companies developing medicines for diseases that affect less than five in 10,000 people. EURORDIS CEO Yann Le Cam makes the case on the organization’s website, “…We believe that rare disease is one of the most dramatic cases of health inequality right now internationally and in Europe in particular…”

Specifically in Europe, the aim of the day was to “promote the explicit inclusion of rare diseases in the third EU public health program, which will decide policy and funding priorities for 2014–2020”, according to EURORDIS’ website.

The European Medicines Agency (EMA), which plays a crucial role in authorization of medicines for rare diseases, supported the event again this year. Indeed, the European Commission grants orphan designation to drugs based on the recommendation of the EMA's Committee for Orphan Medicinal Products. Furthermore, orphan medicines are accessed at a European level rather than in each separate member state. EMA also works closely with FDA in sharing information, and developing common procedures and submitting annual reports on the status of designated orphan medicines. EMA also works with organizations that represent patients through EURORDIS.

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
11%
All of the above.
39%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here